Analysis of cell cycle regulators: p161NK4A, pRb, and CDK4 in low- and high-grade meningiomas

Human Pathology

Volumn 29, Issue 11, 1998, Pages 1200-1207

  Tse, Jenny Y M ^a   Ng, Ho Keung ^a,b   Lo, Kwok Wai ^a   Chong, Edith Y Y ^a   Lam, Paula Y P ^a   Ng, Enders K O ^a   Poon, Wai Sang ^a   Huang, Dolly P ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Meningioma; Methylation; P16INK4A

Indexed keywords

CYCLIN DEPENDENT KINASE; GENE PRODUCT; PROTEIN P16;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL CYCLE G1 PHASE; CLINICAL ARTICLE; DNA METHYLATION; FEMALE; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MALE; MENINGIOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING;

EID: 0031728720     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(98)90246-5     Document Type: Article

References (35)

1. Al Saadi A, Latimer F, Madercic M, et al: Cytogenetic studies of human brain tumours and their clinical significance. Cancer Genet Cytogenet 26:127-141, 1987
2. Rutteledge MH, Xie Y-G, Han F-Y, et al: Deletions of chromosome 22 in sporadic meningiomas. Genes Chromosom Cancer 10:122-130, 1994
3. Ng HK, Lau KM, Tse JYM, et al: Combined molecular genetic studies of chromosome 22q and neurofibromatosis type 2 gene in central nervous system tumours. Neurosurgery 37:764-773, 1995
4. Tse JYM, Ng H-K, Lau K-M, et al: Loss of heterozygosity of chromosome 14q in low- and high-grade meningiomas. HUM PATHOL 28:779-785, 1997
5. van der Riet P, Nawroz H, Hruban RH, et al: Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 54:1156-1158, 1994
6. Olopade OI, Jenkins RB, Ransom DT, et al: Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res 52:2523-2529, 1992
7. Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440, 1994
8. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CKD4. Nature 366:704-707, 1993
9. Cairns P, Polascik TJ, Eby Y, et al: Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genet 11:210-212, 1995
10. Smith-Sorensen B, Hovig E: CDKN2A (p16INK4A) somatic and germline mutations. Hum Mutat 7:294-303, 1996
11. Merlo A, Herman JG, Li M, et al: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1:686-692, 1995
12. Li Y, Nichols MA, Shay JW, et al: Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 54:6078-6082, 1994
13. Yeager T, Stadler W, Belair C, et al: Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 55:493-497, 1995
14. HeJ, Olson JJ, James CD: Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res 55:4833-4836, 1995
15. Doco-Fenzy M, Cornillet P, Scherpereel B, et al: Cytogenetic changes in 67 cranial and spinal meningiomas: Relation to histopathological and clinical pattern. Anticancer Res 13:845-850, 1993
16. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual, vol 1 (ed 2). Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989, p 9.16-9.19
17. Kleihues P, Burger PC, Scheithauer BW: World Health Organization: Histological Typing of Tumours of the Central Nervous System. Berlin, Germany, Springer Verlag
18. de la Monte SM, Flickinger J, Linggood RM: Histopathological features predicting recurrence of meningiomas following subtotal resection. Am J Surg Pathol 10:836-843, 1986
19. Jääskeläinen J, Haltia M, Servo A: Atypical and anaplastic meningiomas: Radiology, surgery, radiotherapy, and outcome. Surg Neurol 25:233-242, 1986
20. Mahmood A, Caccamo DV, Tomecek FJ, et al: Atypical and malignant meningiomas: A clinicopathological review. Neurosurgery 33:955-963, 1993
21. Ng HK: Atypical and malignant meningiomas: Any easy diagnostic criteria? Adv Anat Pathol 1:44-48, 1994
22. Costello JF, Berger MS, Huang H-JS, et al: Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56:2405-2410, 1996
23. Lo K-W, Cheung S-T, Leung S-F, et al: Hypermethylation of the p16 gene in nasopharyngeal carcinoma. Cancer Res 56:2721-2725, 1996
24. Batova A, Diccianni MB, YuJC, et al: Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res 57:832-836, 1997
25. Medema RH, Herrera RE, Lam F, et al: Growth suppression by p16/INK4 requires functional retinoblastoma protein. Proc Natl Acad Sci U S A 92:6289-6293, 1995
26. Sato K, Schäuble B, Kleihues P, et al: Infrequent alterations of the p15, p16, CDK4 and cyclin D1 genes in non-astrocytic human brain tumors. IntJ Cancer 66:305-308, 1996
27. Ono Y, Ueki K, Joseph JT, et al: Homozygous deletions of the CDKN2/p16 gene in dural hemangiopericytomas. Acta Neuropathol 91:221-225, 1996
28. Weber RG, Bostrom J, Wolter M, et al: Analysis of genomic alterations in benign, atypical, and anaplastic meningiomas: Toward a genetic model of meningioma progression. Proc Natl Acad Sci U S A 94:14719-14724, 1997
29. Herman JG, Graff JR, Myohanen S, et al: Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821-9826, 1996
30. Schmidt EE, Ichimura K, Messerie KR, et al: Infrequent methylation of CDKN2A (MTS1/p16) and rare mutation of both CDKN2A and CDKN2B (MTS2/p15) in primary astrocytic tumours. BrJ Cancer 75:2-8, 1997
31. Boyes J, Bird A: Repression of genes by DNA methylation depends on CpG density and promoter strength: evidence for involvement of a methyl-CpG binding protein. EMBO J 11:327-333, 1992
32. Hsieh C-L: Dependence of transcriptional repression on CpG methylation density. Mol Cell Biol 14:5487-5494, 1994
33. Tam SW, Shay JW, Pagano M: Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16INK4. Cancer Res 54:5816-5820, 1994
34. Diedrich U, Lucius J, Bittermann H-J, et al: Loss of alleles in brain tumours: Distribution and correlations with clinical course. J Neurol 242:707-711, 1995
35. Xu HJ, Hu SX, Benedict WF: Lack of nuclear Rb protein staining in G0/middle G1 cells: Correlation to changes in total Rb protein level. Oncogene 6:1139-1146, 1991